In Colorado, miRagen Therapeutics, a biopharmaceutical company which develops microRNA-targeting therapies for treating diseases and cancer, has acquired Signal Genetics. The acquisition was funded partly by a $40 million investment by Fidelity Management and Research Company, Brace Pharma Capital, Atlas Venture, Boulder Ventures, JAFCO Co., Ltd., MP Healthcare Venture Management, MRL Ventures (Merck), Remeditex Ventures, and others. Signal Genetics, a publicly traded company based in California, has been working on genetic testing technology for multiple myeloma. Signal’s name and stock symbol will be changed to that of miRagen Therapeutics, as miRagen acquired 96% of Signal’s stock. Signal’s executives and directors will all resign as part of the acquisition.
Latest article
Meatable hosts distinguished guests for EU’s first cultivated meat tasting
In the Netherlands, Meatable has hosted the European Union’s first cultivated meat tasting. Michelin-starred chef Ron Blaauw; Constantijn van Oranje, Prince of the Netherlands...
Cool as a cucumber (coating): Sweden’s Saveggy raises $2.1 million for edible produce preserver
In Sweden, foodtech startup Saveggy has raised €1.76 (US$2.1 million) to scale up an edible cucumber coating made from a proprietary formula of canola...
Designer develops chitin-based seed pods
In New York, designer Mara Zimmerman has developed SEAD, a seed delivery and cultivation material made from discarded seafood cells.
Specifically, Zimmerman uses chitin from...